These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 16331291)
1. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Jayamanne A; Greenwood R; Mitchell VA; Aslan S; Piomelli D; Vaughan CW Br J Pharmacol; 2006 Feb; 147(3):281-8. PubMed ID: 16331291 [TBL] [Abstract][Full Text] [Related]
2. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915 [TBL] [Abstract][Full Text] [Related]
3. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. Slivicki RA; Xu Z; Mali SS; Hohmann AG Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035 [TBL] [Abstract][Full Text] [Related]
4. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis. Hasanein P; Shahidi S; Komaki A; Mirazi N Eur J Pharmacol; 2008 Sep; 591(1-3):132-5. PubMed ID: 18593578 [TBL] [Abstract][Full Text] [Related]
5. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy. Nasirinezhad F; Jergova S; Pearson JP; Sagen J Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617 [TBL] [Abstract][Full Text] [Related]
6. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883 [TBL] [Abstract][Full Text] [Related]
8. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. Jhaveri MD; Richardson D; Kendall DA; Barrett DA; Chapman V J Neurosci; 2006 Dec; 26(51):13318-27. PubMed ID: 17182782 [TBL] [Abstract][Full Text] [Related]
9. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. Starowicz K; Makuch W; Korostynski M; Malek N; Slezak M; Zychowska M; Petrosino S; De Petrocellis L; Cristino L; Przewlocka B; Di Marzo V PLoS One; 2013; 8(4):e60040. PubMed ID: 23573230 [TBL] [Abstract][Full Text] [Related]
10. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151 [TBL] [Abstract][Full Text] [Related]
11. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Mitchell VA; Greenwood R; Jayamanne A; Vaughan CW Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1186-90. PubMed ID: 17880375 [TBL] [Abstract][Full Text] [Related]
12. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. Desroches J; Charron S; Bouchard JF; Beaulieu P Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808 [TBL] [Abstract][Full Text] [Related]
13. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model. Anderson WB; Gould MJ; Torres RD; Mitchell VA; Vaughan CW Neuropharmacology; 2014 Jun; 81():224-30. PubMed ID: 24384256 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Holt S; Comelli F; Costa B; Fowler CJ Br J Pharmacol; 2005 Oct; 146(3):467-76. PubMed ID: 16100529 [TBL] [Abstract][Full Text] [Related]
15. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. Naidu PS; Booker L; Cravatt BF; Lichtman AH J Pharmacol Exp Ther; 2009 Apr; 329(1):48-56. PubMed ID: 19118134 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain. Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609 [TBL] [Abstract][Full Text] [Related]
17. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model. Adamson Barnes NS; Mitchell VA; Kazantzis NP; Vaughan CW Br J Pharmacol; 2016 Jan; 173(1):77-87. PubMed ID: 26398331 [TBL] [Abstract][Full Text] [Related]
18. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Kinsey SG; Naidu PS; Cravatt BF; Dudley DT; Lichtman AH Pharmacol Biochem Behav; 2011 Oct; 99(4):718-25. PubMed ID: 21740924 [TBL] [Abstract][Full Text] [Related]
19. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Haller VL; Cichewicz DL; Welch SP Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265 [TBL] [Abstract][Full Text] [Related]
20. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety. Danandeh A; Vozella V; Lim J; Oveisi F; Ramirez GL; Mears D; Wynn G; Piomelli D Psychopharmacology (Berl); 2018 Nov; 235(11):3211-3221. PubMed ID: 30251159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]